The purpose of this Phase 2 study is to determine the safety and effectiveness of study drug INCB054828 in treating subjects with a myeloproliferative or lymphoid neoplasm (a type of blood cancer that causes too many blood cells) that also have a genetic abnormality called 8p11. Currently, there is a great unmet need for treating this disease population.
INCB054828 is an investigational drug, which means that INCB054828 has not been approved by the US Food and Drug Administration (FDA).
This is an “open label” study. This means that you and the study research staff will know that you are receiving INCB054828.
Detailed eligibility will be reviewed when you contact the study team.